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54% and Germany 45%). An overall increase in co-prescribing of clopidogrel and 
PPIs was observed in all countries from April 2006 to April 2009 except for France 
where omeprazole co-prescribing decreased in 2008–2009. The most frequently pre-
scribed PPI in combination with clopidogrel was omeprazole in all three countries 
(58% in the UK, 36% in France and 65% in Germany) The second most frequently 
used PPI was lansoprazole in the UK (36%), pantoprazole in Germany (21%) and 
esomeprazole in France (28%). The proportion of clopidogrel patients who were 
co-prescribed lansoprazole was 36% in the UK and only 11% in France and 2% in 
Germany. CONCLUSIONS: Overall prescribing of PPIs with clopidogrel after ACS 
is common in the UK, France and Germany. Since the publication of the OCLA study 
in 2008 no decrease in concurrent prescribing of clopidogrel and omeprazole was 
observed except in France. Revisions of national guidelines and the clopidogrel label 
in 2009 may further affect prescribing of PPIs, and especially omeprazole, with clopi-
dogrel in the future.
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OBJECTIVES: A previous study indicated that increasing nurse stafﬁ ng levels in 
Belgian general cardiac postoperative nursing units was associated with lower mortal-
ity rates. The aim of this study is to conduct a cost-effectiveness analysis of increasing 
nurse stafﬁ ng levels to the level of the 75th percentile in Belgian general cardiac post-
operative nursing units from a hospital perspective. METHODS: The intervention was 
an increase in the number of nursing hours per patient day to the 75th percentile for 
nursing units staffed below that level. The comparator was a “do nothing” alternative. 
Data on nurse stafﬁ ng levels were extracted from the Belgian Nursing Minimum Data 
set and data on in-hospital mortality from the Belgian Hospital Discharge Database. 
The number of life-years gained was calculated by multiplying the number of avoided 
deaths by the life expectancy of patients having a coronary artery bypass graft and 
patients having heart valve procedures. To this effect, survival rates were derived from 
the literature. National cost estimates for the year 2007 were used. Results were 
expressed in the form of the additional costs per avoided death and the additional 
costs per life-year gained. RESULTS: The costs of increasing nurse stafﬁ ng levels to 
the 75th percentile in Belgian general cardiac postoperative nursing units amounted to 
c1,211,022. Such nurse stafﬁ ng levels would avoid an estimated number of 45.9 (95% 
CI: 22.0–69.4) patient deaths per year and generate 458.86 (95% CI: 219.93–693.79) 
life-years gained annually. This corresponds with incremental cost-effectiveness ratios 
of c26,372 per avoided death and c2,639 per life-year gained. Sensitivity analyses 
indicated that the incremental cost-effectiveness ratio was robust to changes in input 
parameters. CONCLUSIONS: Increasing nurse stafﬁ ng levels appears to be a cost-
effective intervention as compared to other cardiovascular interventions.
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MODELING OF HEALTH SERVICE RESEARCH RESULTS WITH UPDATED 
COST DATA—THE GERSHWIN STUDY EXAMPLE
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OBJECTIVES: Health services research is an expanding ﬁ eld of interest for recently 
introduced medical technologies. Complementing efﬁ cacy results with effectiveness 
data illustrates the clinical contribution of a new technology in the real-life setting. 
With effectiveness results being relatively stable over time, the change in reimburse-
ment and price decreases have a substantial impact on initial cost-effectiveness con-
siderations. The three-year GERSHWIN study (GERman Stent Health outcomes 
WIthin Normal practice) was designed to determine long-term clinical outcome and 
economic consequences of Sirolimus-eluting stents (SES) versus bare-metal stents BMS 
in the treatment of CAD from a societal prospective. Economic analysis resulted in 
an ICER of c29,868 per avoided major adverse coronary events (MACE) based on 
2003 to 2005 prices. Due to substantial price reductions, a remodelling with current 
prices would increase applicability of results by decision-makers. METHODS: Com-
plete intention-to-treat study data were valued and analyzed with 2009 prices for the 
main cost drivers (hospital case rate, incremental stent cost and generic clopidogrel 
price). Sensitivity analyses were conducted to evaluate the robustness of the results 
and included a low- and high-cost scenario. RESULTS: Initial hospitalization costs 
were c1157 higher per patient receiving SES, driven primarily by the incremental 
acquisition cost for SES compared BMS. Follow-up direct costs were similar in both 
groups of patients, however the indirect costs in SES patients were signiﬁ cantly lower. 
Overall 36-month MACE-related costs were c283 not signiﬁ cantly higher in the SES 
group (p = 0.62). The ICER based on 2009 cost data resulted in c5320 per MACE 
avoided. Variation of incremental SES prices between c650 and c750 showed no 
signiﬁ cant impact. CONCLUSIONS: Incorporating updated cost data can drastically 
change the ICER generated from health services research projects. Modelling with 
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OBJECTIVES: NHS North Yorkshire and York commissioned York Health Econom-
ics Consortium to carry out an evaluation of their recent Telehealth pilot involving 
patients with long-term conditions. The ﬁ ndings from the evaluation will be used to 
inform plans for the further rollout of Telehealth in North Yorkshire. METHODS: 
Three approaches were employed: a questionnaire was used to obtain details about 
the Telehealth experiences of users and their carers; Case Managers and Community 
Matrons with Telehealth patients on their caseloads were interviewed about referral 
criteria and the impact of Telehealth on their role and patient care; Health care 
resource use data were analyzed. Some caution should be used when generalizing 
ﬁ ndings due to the small sample size and the speciﬁ c characteristics of pilot Telehealth 
recipients. RESULTS: Forty-eight questionnaires were handed out and twenty 
returned (42%). Overall, respondents were happy with Telehealth (90%). Results 
showed that the installation process had been smooth (75%); individuals had received 
sufﬁ cient tuition (95%); they were conﬁ dent using the equipment (95%); and were 
happy with the service received from the monitoring centre (95%). Telehealth gave 
users peace of mind and helped them to manage their own health condition. However, 
a number of users had experienced technical issues (during installation and when 
taking daily measurements). Although there had been some teething problems, mainly 
in relation to the installation process and the monitoring system, clinicians were 
broadly supportive of Telehealth. There was a repeated view that individual patient 
characteristics needed to be taken into account when identifying patients who would 
beneﬁ t from Telehealth. The impact of Telehealth on health care resource use was 
difﬁ cult to determine within the eight month timescale of the pilot. CONCLUSIONS: 
Telehealth gives users peace of mind and helps them manage their health; however, 
its impact on health care resource use is still unclear.
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OBJECTIVES: This analysis aims to explore management of acute coronary syn-
dromes (ACS) from acute event to hospital discharge in Austria, and to measure 
Quality of Life (QoL) at discharge. METHODS: This 12-month international, pro-
spective, observational study recruited ACS patients in selected hospitals undergoing 
percutaneous coronary intervention (PCI), April 2008–March 2009, capturing prac-
tice patterns, resource use and QoL. RESULTS: A total of 148 ACS-PCI patients (out 
of the 152 recruited) were eligible: median age 60 yrs (IQR 51–69), median weight 
80 kg (IQR 70–89), 20% female, 28% Type II diabetics, and 17% prior myocardial 
infarction (MI). Index diagnosis was: unstable angina or non-ST-elevation MI (UA/
NSTEMI)-44% and ST-elevation MI (STEMI)-56%. Almost all patients (96%) 
received stents: 28% bare metal stents only, 70% drug eluting stents only and 2% 
both. Time from start of ACS symptoms to PCI was ≤3 days in 86% of UA/NSTEMI 
patients and ≤1 day in 98% of STEMI patients. Oral antiplatelet medications with 
loading dose (LD) used: aspirin-97% and clopidogrel-91%. Clopidogrel LD was 
administered in the ambulance-9%, previous hospital-10%, emergency room-41%, 
CCU or ICU-31%, catheterization lab-5%, or other ward-5%. LD was administered 
between 6 hours before to 6 hours after PCI in 82% of cases. The ﬁ rst clopidogrel 
LD was 600 mg in 85% and 300 mg in 10% of cases and in-hospital maintenance 
dose was 75 mg in 97%. At time of hospital discharge, 97% of the discharged patients 
were prescribed clopidogrel (discharge dose 75 mg for all patients except one). QoL 
in discharged patients was good: median EQ-5D health state index at 1.00 (IQR 
0.81–1.00). CONCLUSIONS: These real life data reﬂ ect treatment patterns among 
ACS patients managed by PCI in selected hospitals in Austria in 2008–2009. Timing 
and place of loading of antiplatelet agents differ. The QoL of patients at discharge 
was high.
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for patients with acute coronary syndrome (ACS); 
however, reimbursement for antiplatelet therapy differs by EU country and is depen-
dent upon the use of bare metal (BMS) or drug-eluting (DES) stents during percutane-
ous coronary intervention (PCI). Dual antiplatelet (clopidogrel + aspirin) treatment 
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patterns were assessed at 6 months following hospital discharge for patients who 
received only BMS and for patients with at least 1 DES. METHODS: A prospective, 
observational registry of 11 European countries grouped into 6 clusters recruited ACS 
patients undergoing PCI from 2008–2009. Interventional cardiologists collected data 
from ACS events up to hospital discharge, and primary care physicians and cardiolo-
gists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 
(97%) had 6-month data, of which 2842 (96%) received a stent at index PCI. The 
percentage of patients with at least 1 DES was 17% in the Czech Republic, 31% in 
Germany, 33% in Austria-Hungary, 33% in Belgium-The Netherlands, 37% in the 
Nordic countries, and 81% in Greece. The percentage of patients taking dual anti-
platelet therapy at hospital discharge ranged from 93% in Belgium-The Netherlands 
to 100% in Greece for BMS only and from 93% in Belgium-The Netherlands to 100% 
in Czech Republic for patients with DES. At 6 months, the percentage of patients 
taking dual antiplatelet therapy ranged from 45% in Czech Republic to 97% in Greece 
for BMS-only patients and from 83% in Belgium-The Netherlands to 97% in Greece 
for patients with DES. Aspirin use ranged from 89% to 100% across the countries 
and type of stent. CONCLUSIONS: Use of DES versus BMS varied among the Euro-
pean countries. In patients with BMS, there was marked variability with clopidogrel 
use at 6 months; whereas, in patients with DES, clopidogrel was used more frequently 
and with less variability.
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for all patients with acute coronary syndrome 
(ACS). The variations in antiplatelet treatment patterns at 6 months following hospital 
discharge were assessed in patients with unstable angina (UA), non-ST-elevation 
myocardial infarction (NSTEMI), and ST-elevation MI (STEMI) undergoing percuta-
neous intervention (PCI). METHODS: A prospective, observational registry of 11 
European countries grouped into 6 clusters recruited acute coronary syndrome (ACS) 
patients undergoing PCI from 2008–2009. Interventional cardiologists collected data 
from ACS events up to hospital discharge, and primary care physicians and cardiolo-
gists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 
patients (97%) had 6 month data; 51% of patients presented with STEMI and 49% 
with UA/NSTEMI. The median age was 62 yrs. At 6 months following hospital dis-
charge, the percentage of UA/NSTEMI and STEMI patients using clopidogrel, respec-
tively, was 70% and 40% in the Czech Republic, 84% and 89% in Germany, 98% 
and 99% in Greece, 78% and 81% in the Nordic countries, 93% and 94% in Austria 
and Hungary, and 81% and 88% in Belgium and the The Netherlands. The percentage 
of UA/NSTEMI and STEMI patients taking aspirin, respectively, was 98% and 99% 
in the Czech Republic, 89% and 90% in Germany, 97% and 100% in Greece, 95% 
and 93% in the Nordic countries, 94% and 96% in Austria and Hungary, and 91% 
and 94% in Belgium and the The Netherlands. CONCLUSIONS: Use of clopidogrel 
varied considerably between European countries at 6 months after discharge, whereas 
the majority (≥90%) of patients continued to use aspirin. Results suggest that both 
physician and patient education on continuing dual antiplatelet therapy may be 
needed.
PCV133
PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY 
SYNDROME PATIENTS IN 2008–2009: BASELINE RESULTS FOR 
GERMANY FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL 
REGISTRY II (APTOR II)
Zeymer U1, Norrbacka K2, Paget MA3, Goedicke J4, Clouth J5
1Herzzentrum Ludwigshafen, Ludwigshafen, Germany; 2Eli Lilly & Company, Vantaa, Finland; 
3Lilly France S.A., Suresnes Cedex, France; 4Eli Lilly & Company, Hamburg, Germany; 5Lilly 
Deutschland GmbH, Bad Homburg, Hessen, Germany
OBJECTIVES: This analysis aims to explore management of acute coronary syn-
dromes (ACS) from acute event to hospital discharge in Germany, and to measure 
Quality of Life (QoL) at discharge. METHODS: This 12-month international prospec-
tive, observational study recruited ACS patients undergoing percutaneous coronary 
intervention (PCI), April 2008–March 2009, capturing practice patterns, resource use 
and QoL. RESULTS: 500 ACS-PCI patients (out of the 508 recruited) were eligible: 
median age 63 yrs (IQR 53–72), median weight 82 kg (IQR 74–92), 23% female, 
24% Type II diabetics, and 27% prior myocardial infarction (MI). Index diagnosis 
was: unstable angina or non-ST-elevation MI (UA/NSTEMI)-53% and ST-elevation 
MI (STEMI)-47%. Almost all patients (96%) received stents: 68% bare metal stents 
(BMS) only, 29% drug eluting stents (DES) only and 3% both. Time from start of 
ACS symptoms to PCI was 3 days or less in 91% of UA/NSTEMI patients and 1 day 
or less in 97% of STEMI patients. Oral antiplatelet medications with loading dose 
(LD) used: aspirin-86% and clopidogrel-93%. Clopidogrel LD was administered in 
the ambulance-7%, previous hospital-8%, emergency room-32%, CCU or ICU-23%, 
catheterization lab-25%, other ward 5%. LD was administered just before or direct 
after PCI in 79% of cases. The clopidogrel LD was 600 mg in 68% and 300 mg in 
24% of cases and in-hospital maintenance dose (MD) was 75 mg in 98%. At time of 
hospital discharge, 92% of discharged patients were receiving clopidogrel (discharge 
dose 75 mg in all cases). QoL in discharged patients was good: median EQ-5D health 
state index at 0.85 (IQR 0.73–1.00). CONCLUSIONS: These real life data reﬂ ect 
treatment patterns among ACS patients managed by PCI in Germany in 2008–2009. 
Timing and place of antiplatelet loading differ between patients. The QoL of patients 
at discharge was high.
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OBJECTIVES: This study estimated market shares for six statins based on 1) the 
literature-determined lipid-lowering potential of the drugs, and 2) the distribution of 
U.S. adults depending on the amount of lipid-lowering they required. Estimated 
market shares were compared with actual market shares. METHODS: Two panels 
(1999–2000 and 2001–2002) from the National Health and Nutrition Examination 
Survey (NHANES) provided interview, demographic, and laboratory data for 3324 
people >20 years of age who were not taking a statin. In accordance with the ATP III 
Guidelines, coronary heart disease (CHD) and CHD-risk-equivalent events including 
diabetes, other risk factors such as smoking and high blood pressure, and Framingham 
scores to obtain 10-year risk estimates were identiﬁ ed and calculated, respectively for 
each person, along with percentage LDL-C lowering required to reach his or her 
LDL-C goal. Depending on the amount of lowering needed and on whether the 
individual had a liver condition, hence, enhanced risk of rhabdomyolysis, a particular 
statin or particular statins with equal probabilities were assigned to the individual; 
e.g., a person without a liver condition requiring 50% lowering of LDL-C would be 
assigned rosuvastatin or atorvastatin, each with probability = 0.5. RESULTS: Of 1643 
men surveyed, 57.88% were in the lowest-risk group (0–1 risk factors); 14.36% were 
in the highest-risk group (CHD or CHD-risk-equivalent). For the 1681 women, these 
percentages were 73.11% and 11.30%, respectively. Of people needing a statin, 
73.74% needed LDL-C lowering by <25%; only 1.16% required LDL-C lowering of 
>60%. Therapeutic market shares were estimated at 20.11% (rosuvastatin); 18.94% 
(atorvastatin); 17.89% (simvastatin); 16.96% (lovastatin); 13.05% (ﬂ uvastatin); and 
13.05% (pravastatin). CONCLUSIONS: Actual market shares are signiﬁ cantly differ-
ent from market shares based on lipid-lowering considerations. Explanations include 
direct-to-consumer advertising; varying pricing strategies; and clinical trials for addi-
tional indications and subpopulations conducted only by the market leaders.
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OBJECTIVES: By creating incentives around quality and efﬁ ciency, there exists con-
sideration to bundle hospital and physician payments around the episodes of inpatient 
surgery. We provided current payments around surgical episodes including the degree 
to which different types of providers are involved. In particular, we looked at the most 
expensive procedure performed commonly on the elderly: coronary artery bypass graft 
(CABG) surgery. METHODS: The study was based on complete national U.S. claims 
data. Managed care patients were excluded (16% in 2005) from the study because 
service provided to them was not consistently captured in the data set. We also 
excluded patients who were less than 65 years of age or over 99, and those not enrolled 
in the data set at the time of their procedures (4%). Also excluded were patients who 
were nursing home residents before surgery. Patients undergoing CABG were identi-
ﬁ ed using ICD-9 codes. Price-standardized payments from the date of admission for 
the index procedure to 30 days post-discharge were determined and categorized by 
payment type (hospital, physician, and post-acute care) and sub-type. RESULTS: The 
average total payment around an inpatient surgery episode was $45,358 for CABG. 
Hospital payments accounted for the largest of total payments (60% of the procedure), 
followed by physician payments (13%). Diagnosis-Related Group (DRG) payments 
and surgeon and anesthesia professional payments together accounted for 65% of 
total payments. Among payment types potentially leveraged by bundled payments, 
30-day readmissions accounted for 10% of total payments around surgical episodes. 
Post-acute care, including home health care and extended care facilities, accounted for 
7% of total payments. CONCLUSIONS: Payments for potentially mutable services, 
including outlier payments, 30-day readmissions, and post-acute care are considerable 
and might be reduced by incentives for hospitals and physicians to improve quality 
and efﬁ ciency.
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OBJECTIVES: Construct the disease management model for patients with Atrial 
Fibrillation (AF) in Greece, according to initial therapeutic approach. METHODS: 
The analysis was based on data from patient records of 149 geographically distributed 
cardiologists, extracted via strictly structured questionnaire-based interviews. Partici-
